Form 4: Theravance Biopharma Executive Aine Miller Reports Acquisition of 75,000 Ordinary Shares
SEC Form 4 Filing
Aine Miller, SVP at Theravance Biopharma, reports acquiring 75,000 ordinary shares on February 28, 2025.
Summary
- A Form 4 filing reveals that Aine Miller, SVP, DEV & HEAD OF IRE OFFICE at Theravance Biopharma, acquired 75,000 ordinary shares on February 28, 2025.
- The shares were acquired at a price of $0.
- Following the transaction, Miller directly owns 214,261 ordinary shares.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing a transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives.
Stakeholder Impact
- The transaction may have a minor impact on shareholders by slightly increasing the number of shares held by insiders.
Key Dates
| Date | Description |
|---|---|
| 02/28/2025 | Date of transaction: Aine Miller acquired 75,000 ordinary shares. |
| 03/04/2025 | Date of signature on the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.